12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PH-10: Phase IIc data

Top-line data from the single-blind, U.S. Phase IIc PH-10-PS-23 trial in 99 patients with mild to moderate plaque psoriasis of the trunk and/or extremities showing that 23-29% of patients receiving once-daily topical 0.002%, 0.005% or 0.01% PH-10 achieved complete or near complete resolution of all PSI...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >